IDEAYA Biosciences, Inc.
IDYA
$28.32
$0.110.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 55.37% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 55.37% | -- | -- | -- |
| Cost of Revenue | 35.04% | -38.22% | 45.21% | 36.11% | 65.60% |
| Gross Profit | -25.79% | 43.14% | 318.44% | -36.11% | -65.60% |
| SG&A Expenses | 43.51% | 72.04% | 68.25% | 40.27% | 64.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.40% | -30.23% | 48.57% | 36.78% | 65.41% |
| Operating Income | -28.62% | 34.39% | 262.13% | -36.78% | -65.41% |
| Income Before Tax | -36.52% | 36.10% | 330.11% | -46.84% | -82.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.52% | 36.10% | 330.11% | -46.84% | -82.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.52% | 36.10% | 330.11% | -46.84% | -82.40% |
| EBIT | -28.62% | 34.39% | 262.13% | -36.78% | -65.41% |
| EBITDA | -28.72% | 34.63% | 264.53% | -36.98% | -66.24% |
| EPS Basic | -35.99% | 36.99% | 324.01% | -29.40% | -55.04% |
| Normalized Basic EPS | -35.98% | 40.12% | 324.03% | -29.38% | -55.06% |
| EPS Diluted | -35.99% | 36.73% | 321.19% | -29.40% | -55.04% |
| Normalized Diluted EPS | -35.98% | 40.12% | 321.10% | -29.38% | -55.06% |
| Average Basic Shares Outstanding | 0.39% | 1.42% | 2.71% | 13.48% | 17.64% |
| Average Diluted Shares Outstanding | 0.39% | 1.42% | 4.06% | 13.48% | 17.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |